Irritable Bowel Syndrome

Parents in the active disease group indicated greater levels of anxiety than parents of children without active IBD, suggesting a correlation between parental mental health and their child’s disease activity.

Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.

Results from both studies showed the safety of filgotinib for the treatment of ulcerative colitis compared to placebo treatment groups.

Nearly half of patients with IBD in remission experienced abdominal pain, which was associated with sex, fatigue, and depressive symptoms.

The greatest level of treatment discontinuation was seen among patients aged 18-24 years, highlighting an increased risk of early disease relapse.

Analysis showed a higher proportion of patients with CD with NAFLD, varying across studies and regions.

Vedolizumab, anti-TNF, and 5-ASA treatments were not linked to an increased risk of CDI, but investigators noted other baseline variables were significantly associated with CDI risk in patients with IBD.

A population-based cohort study highlighted an association between AD and IBD with risk varying by age, AD severity, and subtype of IBD.

Findings from a recent study of patients with IBD on biologic therapy suggest selenium and zinc deficiencies may predict disease outcomes and adverse clinical effects.

Patients receiving systemic corticosteroids faced an increased risk of severe COVID-19 requiring hospitalization or mechanical ventilation compared to other medication classes used to treat IBD.

When evaluating patient-education strategies among individuals with IBD, investigators found vaccine uptake was unaffected by educational videos and text-based interventions, identifying prior vaccine receipt as the strongest predictor of future vaccination.

A protein targeted by some marketed lipid-lowering agents may increase risk of developing irritable bowel disease.

The first known dose-effect relationship study between colorectal neoplasia and smoking in patients with IBD strengthens the importance of achieving cessation.

A study from China suggests calcium and magnesium malnutrition is associated with Crohn's disease inflammation and activity.

A cross-sectional analysis from China suggests approximately 1 in 10 individuals suffer from incontinence, though not all are seeking adequate care or specialist consultation.

The Cleveland Clinic fellow explains why is upadacitinib is an essential tool in treating Crohn’s disease, especially in those who have previously failed conventional or biologic therapies.

The treatment represents the first approval for pediatric patients with functional constipation.

Kiwifruit supplementation did not have an impact on stool frequency or consistency, but magnesium oxide supplementation did result in improved stool frequency.

The linaclotide group had significant improvements from baseline in the 12 week SBM frequency rate and 12-week stool consistency.

Rates of key safety events, such as malignancies and major adverse cardiovascular events, were comparable among patients receiving placebo and ustekinumab.

Patients with IBD who were treated with advanced therapies who obtained clinical remission had 1.6 times more likely to maintain remission when compared with those who achieved clinical response without remission.

In addition, 17 female patients who completed PENFS showed improvements in various symptoms, such as pain, disability, and catastrophizing, while carbohydrate degradation and LCFA synthesis pathways decreased in the post-treatment and follow-up analysis.

The majority of patients felt it was important for healthcare providers talk to them about the symptoms, possible treatments. In addition, most patients are not prescribed a medication right away.

Previous trials using acupuncture in patients with irritable bowel syndrome have suffered from problems of high placebo response rates.

Twelve additional weeks of subcutaneous risankizumab induction was efficacious and well-tolerated in patients with Crohn's disease following an initial risankizumab 12-week induction dose.